SOPHiA GENETICS (NASDAQ:SOPH) CEO Jurgi Camblong Sells 4,486 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Jurgi Camblong sold 4,486 shares of the firm’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $4.77, for a total value of $21,398.22. Following the sale, the chief executive officer directly owned 3,302,839 shares of the company’s stock, valued at $15,754,542.03. The trade was a 0.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

SOPHiA GENETICS Trading Up 0.2%

NASDAQ SOPH traded up $0.01 during trading hours on Friday, reaching $4.87. The company had a trading volume of 94,648 shares, compared to its average volume of 208,394. The stock has a 50-day moving average of $4.88 and a 200 day moving average of $4.51. SOPHiA GENETICS SA has a 1-year low of $2.58 and a 1-year high of $5.70. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. The stock has a market capitalization of $333.61 million, a P/E ratio of -9.55 and a beta of 1.13.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. The company had revenue of $21.71 million for the quarter, compared to analyst estimates of $21.20 million. As a group, research analysts anticipate that SOPHiA GENETICS SA will post -0.96 earnings per share for the current fiscal year.

Institutional Trading of SOPHiA GENETICS

A number of large investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares during the period. Ensign Peak Advisors Inc acquired a new position in shares of SOPHiA GENETICS during the second quarter worth about $775,000. Archon Capital Management LLC purchased a new stake in shares of SOPHiA GENETICS during the second quarter worth approximately $997,000. Federated Hermes Inc. raised its holdings in SOPHiA GENETICS by 16.4% in the second quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock valued at $682,000 after acquiring an additional 31,000 shares in the last quarter. Finally, Akre Capital Management LLC lifted its stake in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after acquiring an additional 1,481,636 shares during the last quarter. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Analyst Upgrades and Downgrades

SOPH has been the topic of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Guggenheim increased their target price on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, BTIG Research restated a “buy” rating and set a $7.00 target price on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $7.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.